Nirmatrelvir-ritonivir, COVID-19, and possible adverse cutaneous reactions.
- Resource Type
- Academic Journal
- Authors
- Albrecht JM; Cooper BR; Waller JD; Presley CL; Pulsipher KJ; Rundle CW; Dellavalle RP; Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA Dermatology Service, U.S. Department of Veterans Affairs Rocky Mountain Regional Medical Center, Aurora, Colorado, USA. Robert.dellavalle@ucdenver.edu.
- Source
- Publisher: University of California, Davis Country of Publication: United States NLM ID: 9610776 Publication Model: Electronic Cited Medium: Internet ISSN: 1087-2108 (Electronic) Linking ISSN: 10872108 NLM ISO Abbreviation: Dermatol Online J Subsets: MEDLINE
- Subject
- Language
- English
Nirmatrelvir-ritonivir (Paxlovid) recently received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19). Literature has linked numerous cutaneous adverse effects to nirmatrelvir and ritonavir, the copackaged tablets within Paxlovid. A review and comparison of these adverse effects to the common cutaneous manifestations of COVID-19 is provided. Numerous drug-to-drug interactions exist between nirmatrelvir-ritonivir and commonly-used medications within dermatology.